Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.

Anti-neutrophil cytoplasmic antibodies (ANCA) are the serological hallmark of small vessel vasculitis, so called ANCA-associated vasculitis. The international consensus requires testing by indirect immunofluorescence (IIF) on human ethanol-fixed neutrophils (ethN) as screening followed by confirmati...

Full description

Bibliographic Details
Main Authors: Mandy Sowa, Kai Grossmann, Ilka Knütter, Rico Hiemann, Nadja Röber, Ursula Anderer, Elena Csernok, Dimitrios P Bogdanos, Maria Orietta Borghi, Pier Luigi Meroni, Peter Schierack, Dirk Reinhold, Karsten Conrad, Dirk Roggenbuck
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4166465?pdf=render
id doaj-279d64785a404f1e80932d748c41afcf
record_format Article
spelling doaj-279d64785a404f1e80932d748c41afcf2020-11-25T01:25:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10774310.1371/journal.pone.0107743Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.Mandy SowaKai GrossmannIlka KnütterRico HiemannNadja RöberUrsula AndererElena CsernokDimitrios P BogdanosMaria Orietta BorghiPier Luigi MeroniPeter SchierackDirk ReinholdKarsten ConradDirk RoggenbuckAnti-neutrophil cytoplasmic antibodies (ANCA) are the serological hallmark of small vessel vasculitis, so called ANCA-associated vasculitis. The international consensus requires testing by indirect immunofluorescence (IIF) on human ethanol-fixed neutrophils (ethN) as screening followed by confirmation with enzyme-linked immunosorbent assays (ELISAs). This study evaluates the combination of cell- and microbead-based digital IIF analysis of ANCA in one reaction environment by the novel multiplexing CytoBead technology for simultaneous screening and confirmatory ANCA testing. Sera of 592 individuals including 118 patients with ANCA-associated vasculitis, 133 with rheumatoid arthritis, 49 with infectious diseases, 77 with inflammatory bowel syndrome, 20 with autoimmune liver diseases, 70 with primary sclerosing cholangitis and 125 blood donors were tested for cytoplasmic ANCA (C-ANCA) and perinuclear ANCA (P-ANCA) by classical IIF and ANCA to proteinase 3 (PR3) and myeloperoxidase (MPO) by ELISA. These findings were compared to respective ANCA results determined by automated multiplex CytoBead technology using ethN and antigen-coated microbeads for microbead immunoassays. There was a good agreement for PR3- and MPO-ANCA and a very good one for P-ANCA and C-ANCA by classical and multiplex analysis (Cohen's kappa [κ] = 0.775, 0.720, 0.876, 0.820, respectively). The differences between classical testing and CytoBead analysis were not significant for PR3-ANCA, P-ANCA, and C-ANCA (p<0.05, respectively). The prevalence of confirmed positive ANCA findings by classical testing (IIF and ELISA) compared with multiplex CytoBead analysis (IIF and microbead immunoassay positive) resulted in a very good agreement (κ = 0.831) with no significant difference of both methods (p = 0.735). Automated endpoint-ANCA titer detection in one dilution demonstrated a very good agreement with classical analysis requiring dilution of samples (κ = 0.985). Multiplexing by CytoBead technology can be employed for simultaneous screening and quantitative confirmation of ANCA. This novel technique provides fast and cost-effective ANCA analysis by automated digital IIF for the first time.http://europepmc.org/articles/PMC4166465?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Mandy Sowa
Kai Grossmann
Ilka Knütter
Rico Hiemann
Nadja Röber
Ursula Anderer
Elena Csernok
Dimitrios P Bogdanos
Maria Orietta Borghi
Pier Luigi Meroni
Peter Schierack
Dirk Reinhold
Karsten Conrad
Dirk Roggenbuck
spellingShingle Mandy Sowa
Kai Grossmann
Ilka Knütter
Rico Hiemann
Nadja Röber
Ursula Anderer
Elena Csernok
Dimitrios P Bogdanos
Maria Orietta Borghi
Pier Luigi Meroni
Peter Schierack
Dirk Reinhold
Karsten Conrad
Dirk Roggenbuck
Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
PLoS ONE
author_facet Mandy Sowa
Kai Grossmann
Ilka Knütter
Rico Hiemann
Nadja Röber
Ursula Anderer
Elena Csernok
Dimitrios P Bogdanos
Maria Orietta Borghi
Pier Luigi Meroni
Peter Schierack
Dirk Reinhold
Karsten Conrad
Dirk Roggenbuck
author_sort Mandy Sowa
title Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
title_short Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
title_full Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
title_fullStr Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
title_full_unstemmed Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
title_sort simultaneous automated screening and confirmatory testing for vasculitis-specific anca.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Anti-neutrophil cytoplasmic antibodies (ANCA) are the serological hallmark of small vessel vasculitis, so called ANCA-associated vasculitis. The international consensus requires testing by indirect immunofluorescence (IIF) on human ethanol-fixed neutrophils (ethN) as screening followed by confirmation with enzyme-linked immunosorbent assays (ELISAs). This study evaluates the combination of cell- and microbead-based digital IIF analysis of ANCA in one reaction environment by the novel multiplexing CytoBead technology for simultaneous screening and confirmatory ANCA testing. Sera of 592 individuals including 118 patients with ANCA-associated vasculitis, 133 with rheumatoid arthritis, 49 with infectious diseases, 77 with inflammatory bowel syndrome, 20 with autoimmune liver diseases, 70 with primary sclerosing cholangitis and 125 blood donors were tested for cytoplasmic ANCA (C-ANCA) and perinuclear ANCA (P-ANCA) by classical IIF and ANCA to proteinase 3 (PR3) and myeloperoxidase (MPO) by ELISA. These findings were compared to respective ANCA results determined by automated multiplex CytoBead technology using ethN and antigen-coated microbeads for microbead immunoassays. There was a good agreement for PR3- and MPO-ANCA and a very good one for P-ANCA and C-ANCA by classical and multiplex analysis (Cohen's kappa [κ] = 0.775, 0.720, 0.876, 0.820, respectively). The differences between classical testing and CytoBead analysis were not significant for PR3-ANCA, P-ANCA, and C-ANCA (p<0.05, respectively). The prevalence of confirmed positive ANCA findings by classical testing (IIF and ELISA) compared with multiplex CytoBead analysis (IIF and microbead immunoassay positive) resulted in a very good agreement (κ = 0.831) with no significant difference of both methods (p = 0.735). Automated endpoint-ANCA titer detection in one dilution demonstrated a very good agreement with classical analysis requiring dilution of samples (κ = 0.985). Multiplexing by CytoBead technology can be employed for simultaneous screening and quantitative confirmation of ANCA. This novel technique provides fast and cost-effective ANCA analysis by automated digital IIF for the first time.
url http://europepmc.org/articles/PMC4166465?pdf=render
work_keys_str_mv AT mandysowa simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT kaigrossmann simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT ilkaknutter simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT ricohiemann simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT nadjarober simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT ursulaanderer simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT elenacsernok simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT dimitriospbogdanos simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT mariaoriettaborghi simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT pierluigimeroni simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT peterschierack simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT dirkreinhold simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT karstenconrad simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
AT dirkroggenbuck simultaneousautomatedscreeningandconfirmatorytestingforvasculitisspecificanca
_version_ 1725114932931854336